US009408862B2

(12) **United States Patent**
Tabuteau

(10) **Patent No.: US 9,408,862 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS**

(71) Applicant: **Antecip Bioventures II LLC**, New York, NY (US)

(72) Inventor: **Herriot Tabuteau**, New York, NY (US)

(73) Assignee: **ANTECIP BIOVENTURES II LLC**, New York, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/968,514**

(22) Filed: **Dec. 14, 2015**

(65) **Prior Publication Data**

US 2016/0095872 A1 Apr. 7, 2016

Related U.S. Application Data

(63) Continuation of application No. 14/540,333, filed on Nov. 13, 2014, now Pat. No. 9,216,168, which is a continuation of application No. 14/481,097, filed on Sep. 9, 2014, now Pat. No. 8,962,599, which is a continuation of application No. 14/288,720, filed on May 28, 2014, now Pat. No. 8,865,757, said application No. 14/540,333 is a continuation of application No. 14/288,241, filed on May 27, 2014, now Pat. No. 8,901,161.

(51) **Int. Cl.**

C07D 233/60	(2006.01)
A61K 31/4172	(2006.01)
A61K 31/4164	(2006.01)
A61K 31/675	(2006.01)
C07F 9/6506	(2006.01)
A61K 9/00	(2006.01)
A61K 9/20	(2006.01)
A61K 9/48	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/675*** (2013.01); ***A61K 9/0053*** (2013.01); ***A61K 9/20*** (2013.01); ***A61K 9/48*** (2013.01); ***A61K 31/4164*** (2013.01); ***A61K 31/4172*** (2013.01); ***C07D 233/60*** (2013.01); ***C07F 9/65061*** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,939,130	A	7/1990	Jaeggi et al.
5,869,471	A	2/1999	Hovancik et al.
6,015,801	A	1/2000	Daifotis
6,419,955	B1	7/2002	Gabel et al.
6,943,155	B2	9/2005	Lichtenberger
7,658,939	B2	2/2010	Oshlack et al.
7,704,977	B2	4/2010	Leonard
8,053,429	B2	11/2011	Cumming et al.
8,119,159	B2	2/2012	Cumming et al.
8,323,689	B2	12/2012	Cumming et al.
8,323,690	B2	12/2012	Cumming et al.
8,399,023	B2	3/2013	Hanna et al.
8,772,267	B2	7/2014	Pappagallo
8,828,431	B2	9/2014	Cumming et al.
8,859,530	B2	10/2014	Desai
8,865,757	B1	10/2014	Tabuteau
8,883,201	B2	11/2014	Leonard
8,883,203	B2	11/2014	Leonard
8,901,161	B1	12/2014	Tabuteau
8,901,162	B1	12/2014	Tabuteau
8,933,057	B2	1/2015	Hanna et al.
9,216,168	B1 *	12/2015	Tabuteau A61K 31/675
2004/0063670	A1	4/2004	Fox et al.
2009/0281064	A1	11/2009	Ahmed et al.
2010/0215743	A1	8/2010	Leonard
2011/0098252	A1	4/2011	Pappagallo
2012/0190647	A1	7/2012	Hanna et al.
2013/0274282	A1	10/2013	Tabuteau
2013/0303485	A1	11/2013	Tabuteau
2013/0303486	A1	11/2013	Tabuteau
2013/0303487	A1	11/2013	Tabuteau
2013/0303488	A1	11/2013	Tabuteau
2014/0051669	A1	2/2014	Tabuteau
2014/0051718	A1	2/2014	Tabuteau
2014/0249107	A1	9/2014	Tabuteau
2014/0249108	A1	9/2014	Tabuteau
2014/0249109	A1	9/2014	Tabuteau
2014/0249111	A1	9/2014	Tabuteau
2014/0249112	A1	9/2014	Tabuteau

(Continued)

FOREIGN PATENT DOCUMENTS

CN	101259133	3/2008
WO	WO2005/107751	11/2005

OTHER PUBLICATIONS

Merrion Pharmaceuticals press release, "MER-101 Tablets: A Pilot Bioavailability Study of a Novel Oral Formulation of Zoledronic Acid," (Oct. 2007; merrionpharma.com/archive/portfolio/oct2007eortcposter.pdf).*

Sharma, Amit et al., "A Web-Based Cross-Sectional Epidemiological Survey of Complex Regional Pain Syndrome", Regional Anesthesia and Pain Medicine, 34(2):110-115 (2009).

Sharma, Amit et al., "Advances in treatment of complex regional pain syndrome: recent insights on a perplexing disease", Curr Opin Anaesthesiol, 19:566-572 (2006).

Sigtermans, Marnix J. et al., "Ketamine produces effective and long-term pain relief in patients with Complex Regional Pain Syndrome Type I", Pain® 145:304-311 (2009).

(Continued)

Primary Examiner — Michael Barker

(74) *Attorney, Agent, or Firm* — K&L Gates LLP; Brent A. Johnson; Louis C. Cullman

(57) **ABSTRACT**

Therapeutic compositions comprising substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain.

30 Claims, No Drawings